Wedbush Morgan Reiterates a 'Buy' on Biodel (BIOD)
More News related to BIOD
- Wedbush Reiterates an 'Outperform' on Biodel (BIOD); Comments on VIAjectT
- Unusual 11 Mid-Day Movers 3/25: CBG, MIC, JBL, HW Higher; DRYS, AIG, AMN, FTBK Lower
- Morning Movers 3/25: CBG, BIOD, ACAS, BBI, AMD Higher; DRYS, SOLF, STZ, CYPB, DSW Lower
- Biodel (BIOD) Plans to Submit NDA for VIAject(R) to FDA
- Wedbush Morgan Reiterates a 'Buy' on Biodel (BIOD)
More News related to Analyst Comments
- After-Hours Movers 11/24: QADI, JCG, ASYS Higher; DRAM, CWTR Lower
- Trading Radar for 11/25: Deere & Co. (DE), Tiffany & Co. (TIF), Conn's (CONN) Report
- Afternoon ETF Check: SMH Up; XLF, TAN, EWJ Down
- Unusual 11 Mid-Day Movers 11/24: IWA, DRAM, ABG, TIXC Higher; WH, WMG, ABIO, NYNY Lower
- Notable Analyst Rating Changes 11/24: ABG, PRU, RS, AYI, AMLN, TLAB Upgraded; DELL, CIEN, UNP, ALV Downgraded
Wedbush Morgan reiterates a 'Buy' on Biodel (Nasdaq: BIOD). Price target $10.
Wedbush analyst says, "Management guided to announcing VIAject regulatory announcement in March. We believe a transforming VIAject partnership announcement could follow in 2009. We anticipate other catalysts in 2009."
Biodel Inc. (Biodel) is a development-stage specialty pharmaceutical company located in Danbury, Connecticut.
Related Categories
Analyst CommentsStocks Mentioned
+0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
